EUVIMEDEUVIMED entdecken
Crossref

A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach

Jie Zhang, Wei Wang, Xiao-Qing Wang, Hai-Rong Hao, Wen Hu, Zong-Li Ding, Li Dong, Hui Liang, Yi-Yuan Zhang, Lian-Hua Kong, Ying Xie

Hepatology International · 2025-08 · 19 (4) · 820-835

DOI: 10.1007/s12072-025-10792-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Hepatology International, online erschienen am 09.04.2025. Verfasst von Jie Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology, Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, China. Hauptthemen laut MEDLINE: Fatty Liver. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: the Natural Science Research Project of Huai'an City, Health Research Project of Huai'an City, Construction Unit of Research Project of Geriatric Clinical Technology Application of Jiangsu Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a critical health concern, with metabolic dysfunction-associated steatohepatitis (MASH) representing a severe subtype that poses significant risks. This study aims to develop a robust diagnostic model for high-risk MASH utilizing a multi-omics approach. METHODS: We initiated proteomic analysis to select differential proteins, followed by liver transcriptional profiling to localize these proteins. An intersection of differential proteins and liver-expressed genes facilitated the identification of candidate biomarkers. Subsequently, scRNA-seq data helped ascertain the subcellular localization of these biomarkers in kupffer cells. We then established two MASLD models to investigate the co-localization of F4/80 and the target proteins in Kupffer cells using immunofluorescence dual-labeling. Correlation analyses were performed using blood samples from a discovery cohort of 144 individuals with liver pathology to validate the relationships between candidate biomarkers and MASLD phenotypes. Using LASSO regression, we established the ABD-LTyG predictive model for high-risk MASH (NAS ≥ 4 + F ≥ 2) and validated its efficacy in an independent cohort of 171 individuals. Finally, we compared this model against three classic non-invasive liver fibrosis diagnostic methods. RESULTS: A proteo-transcriptomic comparison identified 58 consistent biomarkers in plasma and liver, with 25 closely associated with MASLD phenotype. Utilizing single-cell data and the HPA database, we delineated the localization of these biomarkers in liver cells, identifying TREM2, IL18BP, and LGALS3BP predominantly in the Kupffer cell subpopulation. Validation in animal models confirmed elevated expression and cellular localization of TREM2, IL18BP, and LGALS3BP in MASLD. To enhance diagnostic capability, we integrated clinical characteristics using LASSO regression to develop the ABD-LTyG model, comprising AST, BMI, total bilirubin (TB), vitamin D, TyG, and the biomarkers LGALS3BP and TREM2. This model demonstrated an AUC of 0.832 (95% CI 0.753-0.911) in the discovery cohort and 0.807 (95% CI 0.742-0.872) in the validation cohort for diagnosing high-risk MASH, outperforming traditional assessments such as FIB-4, NFS, and APRI. CONCLUSION: The integration of circulating biomarkers and clinical parameters into the ABD-LTyG model offers a promising approach for diagnosing high-risk MASH. This study underscores the importance of multi-omics strategies in enhancing diagnostic accuracy and guiding clinical decision-making.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fatty LiverHumansBiomarkersMaleProteomicsFemaleMiddle AgedKupffer CellsAnimalsNon-alcoholic Fatty Liver DiseaseLiverGene Expression ProfilingMultiomics

Stichwörter der Autor:innen

BiomarkerFibrosisMASLDMulti-omics strategies

Substanzen

Biomarkers

Autor:innen und Institutionen

  • Department of Endocrinology, Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, China.
  • Department of Endocrinology and Metabolism, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an, 223002, Jiangsu, China.
  • Department of Clinical Laboratory / Gastroenterology, Lianshui People's Hospital of Kangda College Affiliated to Nanjing Medical University, Huai'an, 223400, Jiangsu, China.
  • Department of Gereology, Huai'an Hospital Affiliated to Xuzhou Medical University, Huai'an, 223002, Jiangsu, China.
  • Department of Infectious Disease, the First Affiliated Hospital of Nanjing Medical University, 300 Guangzhou Road, Nanjing, 210029, Jiangsu, China.
  • Department of General Surgery and Bariatric and Metabolic Surgery, the First Affiliated Hospital of Nanjing Medical University, Nanjing, 210029, Jiangsu, China.

Förderung

  • the Natural Science Research Project of Huai'an City
  • Health Research Project of Huai'an City
  • Construction Unit of Research Project of Geriatric Clinical Technology Application of Jiangsu Province
  • Scientific Research Project of Elderly Health of Jiangsu Province
  • Major Basic Research Project of the Natural Science Foundation of the Jiangsu Higher Education Institutions
  • the Natural Science Research Project of Huai’an City
  • Health Research Project of Huai’an City

Zitieren

APA

Zhang, J., Wang, W., Wang, X. Q., Hao, H. R., Hu, W., Ding, Z. L., Dong, L., Liang, H., Zhang, Y. Y., Kong, L. H., & Xie, Y. (2025). A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach. Hepatology International, 19(4), 820-835. https://doi.org/10.1007/s12072-025-10792-9

Vancouver

Zhang J, Wang W, Wang XQ, Hao HR, Hu W, Ding ZL, et al. A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach. Hepatology International. 2025;19(4):820-835. doi:10.1007/s12072-025-10792-9

BibTeX
@article{Zhang2025,
  author = {Zhang, Jie and Wang, Wei and Wang, Xiao-Qing and Hao, Hai-Rong and Hu, Wen and Ding, Zong-Li and Dong, Li and Liang, Hui and Zhang, Yi-Yuan and Kong, Lian-Hua and Xie, Ying},
  title = {A robust diagnostic model for high-risk MASH: integrating clinical parameters and circulating biomarkers through a multi-omics approach},
  journal = {Hepatology International},
  year = {2025},
  volume = {19},
  number = {4},
  pages = {820--835},
  doi = {10.1007/s12072-025-10792-9}
}
Kostenlos starten →